ZIVO · Zivo Bioscience, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.6K | $53.4K | $0 | - | $31.5K | $0 | $35.7K | - | $11.8K | $4.0K |
| Cost of Revenue | $44.3K | $35.5K | $0 | - | $22.1K | $0 | $23.2K | - | $0 | $701 |
| Gross Profit | $21.3K | $17.9K | $0 | - | $9.4K | $0 | $12.5K | - | $0 | $3.3K |
| R&D | $203.4K | $479.7K | $2.77M | - | $326.4K | $2.25M | $312.8K | - | $220.7K | $442.1K |
| SG&A | $836.2K | $1.17M | $1.44M | - | $1.94M | $5.98M | $975.6K | - | $1.36M | $1.39M |
| Total Operating Expenses | $1.04M | $1.65M | $4.21M | - | $2.27M | $8.23M | $1.29M | - | $1.58M | $1.83M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($1.02M) | ($1.63M) | ($4.21M) | - | ($2.26M) | ($8.23M) | ($1.28M) | - | ($1.57M) | ($1.82M) |
| Interest Expense | $13.0K | $7.4K | $2.4K | - | $8.6K | $6.8K | $2.6K | - | $32.7K | $31.8K |
| Income Tax | - | - | - | - | - | - | $0 | - | - | - |
| Net Income | ($1.03M) | ($1.64M) | ($4.21M) | - | ($2.27M) | ($8.24M) | ($1.28M) | - | ($1.82M) | ($2.07M) |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.67) | ($2.78) | ($0.47) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $57.2K | $2.5K | $138.6K | $1.54M | $159.4K | - | - | $274.4K | $1.48M | $21.1K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $993.0K | $860.9K | $655.3K | $547.1K | $787.6K | $1.09M | $705.8K | $993.1K | $643.8K | $1.27M |
| Current Assets | $281.4K | $409.9K | $1.02M | $1.64M | $436.5K | $495.1K | $710.6K | $425.4K | $1.95M | $530.1K |
| Total Assets | $559.5K | $703.3K | $1.33M | $1.64M | $495.6K | $575.6K | $816.4K | $555.7K | $2.10M | $710.3K |
| Current Liabilities | $3.61M | $2.96M | $2.61M | $2.04M | $2.58M | $2.87M | $3.09M | $2.76M | $3.17M | $3.80M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.85M | $3.24M | $2.95M | $2.16M | $2.58M | $2.87M | $3.09M | $2.76M | $3.20M | $3.86M |
| Stockholders' Equity | ($3.29M) | ($2.54M) | ($1.62M) | ($514.9K) | ($2.08M) | ($2.30M) | ($2.27M) | ($2.21M) | ($1.09M) | ($3.14M) |
| Retained Earnings | ($143.85M) | ($142.82M) | ($141.18M) | ($136.97M) | ($135.37M) | ($133.10M) | ($124.86M) | ($123.58M) | ($121.67M) | ($119.85M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.43M) | - | - | - | ($1.70M) | - | - | - |
| Investing Cash Flow | - | - | $0 | - | - | - | $0 | - | - | - |
| Financing Cash Flow | - | - | $405.0K | - | - | - | $1.56M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 32.4% | 33.6% | - | - | 30.0% | - | 35.0% | - | 0.0% | 82.7% |
| Operating margin | -1551.8% | -3057.8% | - | - | -7174.7% | - | -3571.8% | - | -13325.3% | -45033.7% |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -1574.2% | -3071.6% | - | - | -7201.9% | - | -3579.2% | - | -15465.4% | -51125.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 310.0% | 898.2% | - | - | 1036.1% | - | 875.6% | - | 1869.9% | 10916.4% |
| SG&A / Revenue | 1274.2% | 2193.1% | - | - | 6168.7% | - | 2731.2% | - | 11490.4% | 34200.0% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -184.7% | -233.2% | -316.3% | - | -457.8% | -1430.9% | -156.6% | - | -86.8% | -291.5% |
| Return on equity | 31.4% | 64.6% | 260.4% | - | 108.9% | 358.8% | 56.3% | - | 166.8% | 65.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.08 | 0.14 | 0.39 | 0.80 | 0.17 | 0.17 | 0.23 | 0.15 | 0.61 | 0.14 |
| Quick ratio | 0.08 | 0.14 | 0.39 | 0.80 | 0.17 | 0.17 | 0.23 | 0.15 | 0.61 | 0.14 |
| Cash ratio | 0.02 | 0.00 | 0.05 | 0.76 | 0.06 | - | - | 0.10 | 0.47 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -78.6x | -221.9x | -1753.7x | - | -264.0x | -1216.3x | -481.8x | - | -48.0x | -57.4x |
| Equity multiplier | -0.17 | -0.28 | -0.82 | -3.19 | -0.24 | -0.25 | -0.36 | -0.25 | -1.92 | -0.23 |
| Liabilities / Assets | 6.87 | 4.61 | 2.21 | 1.31 | 5.20 | 4.99 | 3.78 | 4.97 | 1.52 | 5.43 |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | 0.08 | 0.00 | - | 0.06 | 0.00 | 0.04 | - | 0.01 | 0.01 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 8175d | 8857d | - | - | 13037d | - | 11096d | - | - | 663059d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 831.0x | 1063.8x | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 108.3% | - | -100.0% | - | 166.9% | -100.0% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 125.3% | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 54.9% | 80.2% | -229.9% | - | -43.7% | -351.2% | 35.2% | - | 21.4% | 11.8% |
| Net income growth (YoY) | 54.5% | 80.1% | -229.4% | - | -24.3% | -297.8% | 35.2% | - | 9.0% | 0.1% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -57.8% | -10.7% | 28.7% | 76.7% | -90.4% | 27.0% | -30.3% | -20666.7% | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Zivo Bioscience against the 5 most active filers in the same SIC group.